Pricing Log in Create free account

Curis, Inc. (CRIS) vs Lyra Therapeutics, Inc. (LYRA)

Curis, Inc. and Lyra Therapeutics, Inc. are both Biotechnology companies. Curis, Inc. is the larger, with a market value of $1.1M against $870.0K — 1.2× the size. Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −74.1%. Curis, Inc. has the higher net margin (0.00% vs −7,266.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Curis, Inc. leads on 11 and Lyra Therapeutics, Inc. on 5.

Valuation

Metric CRIS LYRA Biotechnology median
P/E n/m n/m 8.50
P/S 0.09 0.74 9.71
P/B 0.19 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.41 0.51 0.64
EV/Sales (0.37) (39.19) 9.21
Earnings yield (3,468.29%) (10,078.95%) (33.15%)
Free cash flow yield (3,540.29%) (9,793.95%) (25.50%)

Profitability

Metric CRIS LYRA Biotechnology median
Gross margin 99.52% 100.00% 65.16%
Operating margin 0.00% (7,794.47%) 0.00%
Net margin 0.00% (7,266.08%) 0.00%
Free cash flow margin 0.00% (7,261.06%) 0.00%
Return on equity 455.35% (6,594.98%) (56.36%)
Return on assets (87.76%) (56.45%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRIS LYRA Biotechnology median
Revenue growth (TTM) (13.43%) (74.05%) 6.02%
EPS growth (last fiscal year) 91.57% 73.96% 30.26%
Revenue growth, 5-year CAGR (2.71%) (20.38%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRIS LYRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.49 1.71 4.72
Net debt to EBITDA 0.91 0.52 0.96

Dividend

Metric CRIS LYRA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRIS LYRA Biotechnology median
Market cap 1.06m 870.00k 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack